早熟
LMNA公司
拉明
癌症研究
转基因
吗啉
细胞生物学
生物
基因
早衰
遗传学
斑马鱼
作者
Michael R. Erdos,Wayne A. Cabral,Urraca L. Tavarez,Kan Cao,Jelena Gvozdenovic‐Jeremic,Narisu Narisu,Patricia M. Zerfas,Stacy L. Crumley,Yoseph D. Boku,Gunnar J. Hanson,Dan V. Mourich,Ryszard Kole,Michael Eckhaus,Leslie B. Gordon,Francis S. Collins
出处
期刊:Nature Medicine
[Nature Portfolio]
日期:2021-03-01
卷期号:27 (3): 536-545
被引量:80
标识
DOI:10.1038/s41591-021-01274-0
摘要
Hutchinson-Gilford progeria syndrome (HGPS) is a rare accelerated aging disorder characterized by premature death from myocardial infarction or stroke. It is caused by de novo single-nucleotide mutations in the LMNA gene that activate a cryptic splice donor site, resulting in the production of a toxic form of lamin A, which is termed progerin. Here we present a potential genetic therapeutic strategy that utilizes antisense peptide-conjugated phosphorodiamidate morpholino oligomers (PPMOs) to block pathogenic splicing of mutant transcripts. Of several candidates, PPMO SRP-2001 provided the most significant decrease in progerin transcripts in patient fibroblasts. Intravenous delivery of SRP-2001 to a transgenic mouse model of HGPS produced significant reduction of progerin transcripts in the aorta, a particularly critical target tissue in HGPS. Long-term continuous treatment with SRP-2001 yielded a 61.6% increase in lifespan and rescue of vascular smooth muscle cell loss in large arteries. These results provide a rationale for proceeding to human trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI